Meeting
2021 ASCO Annual Meeting
Predictive value of lymphocyte immunophenotyping (LIP) in primary central nervous system lymphoma (PCNSL).
Authors
Axel Berthelot
APHM, Marseille, France
Axel Berthelot , Celine Boucard , Gregorio Petrirena , Chantal Campello , Olivier L. Chinot , Emeline Tabouret
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Non-Glioma
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2063)
DOI
10.1200/JCO.2021.39.15_suppl.2063
Abstract #
2063
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Lenalidomide in the treatment of relapsed primary central nervous system lymphoma (PCNSL).
First Author: Caroline Houillier
Poster
2013 ASCO Annual Meeting
High-dose methotrexate with and without rituximab for the treatment of newly diagnosed primary CNS lymphoma: Johns Hopkins Hospital experience.
First Author: Matthias Holdhoff
Poster
2023 ASCO Annual Meeting
Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).
First Author: Marion Alcantara
Poster
2020 ASCO Virtual Scientific Program
Ibrutinib-based combination therapy exhibited therapeutic benefit in newly diagnosed primary central nervous system lymphoma.
First Author: Feili Chen